Article
A new kind of drug, a Raf kinase inhibitor, is well-tolerated and may prove effective in treating patients with metastatic melanoma, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Study Evaluates Training Tool Developed for PCP Psoriasis Diagnosis
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Conference Speaker Sneak Peek: Elevate-Derm
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Tirbanibulin Demonstrates Efficacy for Actinic Keratosis in Larger Field Treatment
Safe and Effective: Upadacitinib Shows Promise in PN Treatment